 |
66 Diseases |  |
14 Trials |
|
14 Trials |  |
518 News |  |
| «123456 |
- |||||||||| Kinaction (masitinib) / AB Science
New P2/3 trial, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 13, 2018
P2/3, N=295, Recruiting, Sponsor: AB Science
- | Kinaction (masitinib) / AB Science
Clinical, P3 data, Journal: Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. (Pubmed Central) - Mar 23, 2018
P3
These study findings indicate that masitinib is an effective and well tolerated agent for the treatment of severely symptomatic indolent or smouldering systemic mastocytosis.
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Combination therapy: Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (clinicaltrials.gov) - Apr 25, 2017
P3, N=406, Not yet recruiting, Sponsor: AB Science
- |||| Kinaction (masitinib) / AB Science
Phase classification, Trial primary completion date: Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis (clinicaltrials.gov) - Apr 21, 2017
P2/3, N=450, Recruiting, Sponsor: AB Science
These study findings indicate that masitinib is an effective and well tolerated agent for the treatment of severely symptomatic indolent or smouldering systemic mastocytosis. Phase classification: P2b --> P2/3 | Trial primary completion date: Dec 2014 --> Jan 2019
- ||||||| Kinaction (masitinib) / AB Science
Trial completion, Combination therapy: Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Apr 21, 2017
P2/3, N=394, Completed, Sponsor: AB Science
Phase classification: P2b --> P2/3 | Trial primary completion date: Dec 2014 --> Jan 2019 Active, not recruiting --> Completed
- ||||| Kinaction (masitinib) / AB Science
Enrollment closed, Trial initiation date, Combination therapy: Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jul 22, 2016
P2/3, N=381, Active, not recruiting, Sponsor: AB Science
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Initiation date: Apr 2014 --> Apr 2013
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 16, 2015
P3, N=550, Recruiting, Sponsor: AB Science
- |||||||||| Kinaction (masitinib) / AB Science
New P2/3 trial, Combination therapy: Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Oct 28, 2015
P2/3, N=381, Recruiting, Sponsor: AB Science
- |||| Kinaction (masitinib) / AB Science
Trial primary completion date, Metastases: Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit (clinicaltrials.gov) - Oct 22, 2015
P3, N=200, Recruiting, Sponsor: AB Science
Recruiting --> Active, not recruiting | Initiation date: Apr 2014 --> Apr 2013 Trial primary completion date: Dec 2013 --> Dec 2017
- ||||| Kinaction (masitinib) / AB Science
New P2 trial, Combination therapy, Metastases: Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients (clinicaltrials.gov) - Jul 6, 2015
P2, N=68, Active, not recruiting, Sponsor: AB Science
- ||||| Kinaction (masitinib) / AB Science
Trial initiation date, Stroma: Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib (clinicaltrials.gov) - Jul 17, 2014
P3, N=210, Ongoing, Sponsor: AB Science
Trial primary completion date: Dec 2013 --> Dec 2017 Initiation date: Apr 2012 --> Apr 2013
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Surgery, Stroma: Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence (clinicaltrials.gov) - Dec 10, 2013
P3, N=330, Not yet recruiting, Sponsor: AB Science
- Kinaction (masitinib) / AB Science
New P2 trial: A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) Estudio de fase IIa prospectivo, multic (EUDRACT) - Jun 23, 2013
P2, N=30, Ongoing, Sponsor: AB SCIENCE
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial: Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Jun 5, 2013
P3, N=396, Recruiting, Sponsor: AB Science
- | Kinaction (masitinib) / AB Science
New P2 trial: Evaluation of masitinib in acute ischemic stroke Evaluaci (EUDRACT) - Oct 21, 2012
P2, N=45, Ongoing, Sponsor: AB Science
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Stroma: Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib (clinicaltrials.gov) - Sep 25, 2012
P3, N=208, Recruiting, Sponsor: AB Science
- | Kinaction (masitinib) / AB Science
New P2 trial, Stroma: Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib (clinicaltrials.gov) - Jan 8, 2012
P2, N=44, Active, not recruiting, Sponsor: AB Science
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Combination therapy: A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 9, 2011
P3, N=300, Recruiting, Sponsor: AB Science
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial: Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids (clinicaltrials.gov) - Oct 6, 2011
P3, N=300, Recruiting, Sponsor: AB Science
- | Kinaction (masitinib) / AB Science
New P2 trial: Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Oct 5, 2011
P2, N=35, Completed, Sponsor: AB Science
- |||||||||| Kinaction (masitinib) / AB Science
New P2/3 trial: Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis (clinicaltrials.gov) - Sep 12, 2011
P2/3, N=450, Recruiting, Sponsor: AB Science